Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Maxpro Capital Acquisition Corp.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/21/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events Interactive Data |
| 01/13/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 01/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/28/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 10/14/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 10/07/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/14/2022 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...|
Docs:
|
"Business Combination Agreement, by and among Maxpro Capital Acquisition Corp., Apollomics Inc. and Project Max SPAC Merger Sub, Inc",
"Sponsor Support Agreement, by and among Maxpro Capital Acquisition Corp., Apollomics Inc., MP One Investment LLC and the individuals party thereto",
"Company Shareholder Voting Agreement, by and among Maxpro Capital Acquisition Corp., Apollomics Inc. and certain shareholders party thereto",
"Lock-Up Agreement, by Apollomics Inc., MP One Investment LLC and the individuals party thereto",
"Form of Registration Rights Agreement",
"Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp. - Transaction values Apollomics at pre-money equity value of $899 million - Apollomics is a late-stage clinical biopharmaceutical company developing innovative product candidates for large, unmet medical needs - Broad pipeline of drug candidates across multiple oncology programs; two lead clinical-stage candidates addressing a combined $11 billion non-small cell lung cancer and acute myeloid leukemia market opportunity - Transaction proceeds to accelerate development of late-stage clinical programs, vebreltinib and uproleselan FOSTER CITY, CALIF. and Taipei City, Taiwan – September 14, 2022 – Apollomics Inc. , a late-stage clinical bioph...",
"Investor Presentation, dated September 2022",
"Transcript of Webcast, posted on September 14, 2022",
"Summary Risk Factors" |
|
| 11/26/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 10/19/2021 |
8-K
| Quarterly results |
| 10/13/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...|
Docs:
|
"Underwriting Agreement, between the Company and EF Hutton, division of Benchmark Investments, LLC, as representative of the underwriters named therein",
"Second Amended and Restated Certificate of Incorporation",
"Warrant Agreement, between the Company and Continental Stock Transfer & Trust Company",
"Letter Agreement, among the Company, MP One Investment LLC and each of the executive officers and directors of the Company",
"Investment Management Trust Agreement, between the Company and Continental Stock Transfer & Trust Company",
"Registration Rights Agreement, among the Company and certain securityholders",
"Placement Unit Purchase Agreement, between the Company and MP One Investment LLC",
"Administrative Support Agreement, by and between the Company and Maxpro Capital Management LTD",
"Maxpro Capital Acquisition Corp. Songren Road, Xinyi District",
"Maxpro Capital Acquisition Corp." |
|
|
|